MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. - Wikidata - awgldk - TriplyDB

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

http://www.wikidata.org/entity/Q35803858

about

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1 Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function.Polymorphisms in DNA repair genes and MDR1 and the risk for non-Hodgkin lymphoma.Xenobiotic, bile acid, and cholesterol transporters: function and regulation.Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?Relationship between P-glycoprotein and second-generation antipsychotics.Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies.Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver.Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure.Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis.Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study.Meta-Analysis of ABCB1 3435C>T Polymorphism and Colorectal Cancer.Implications of pharmacogenetics for individualizing drug treatment and for study design.Intestinal drug absorption and bioavailability: beyond involvement of single transport function.Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs.ABC of oral bioavailability: transporters as gatekeepers in the gut.MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients.Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression.Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.HPLC Determination of Fexofenadine in Human Plasma For Therapeutic Drug Monitoring and Pharmacokinetic Studies.The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique.Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans.Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications.Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition.ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research.Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.Multidrug resistance in epilepsy: a pharmacogenomic update.The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient.ESRD impairs nonrenal clearance of fexofenadine but not midazolam.Gender and interindividual variability in pharmacokinetics.Pharmacokinetics in special populations.Drug transporters and renal drug disposition in the newborn.Fexofenadine hydrochloride in the treatment of allergic disease: a review Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes.

P2860

Q28286926-4A139629-D6AF-4D74-9585-B3A17CF95055 Q33460512-E682D677-1F8E-482F-A41D-C88365906ECF Q33580765-1B57C7F2-FCAA-4628-AC2F-258E26235151 Q33714593-6BDD64D6-3D4C-403F-B8BB-3BD494E2235C Q34190195-56B33225-D871-4AB0-B252-5A07D4005C56 Q34208133-BD52F53D-9266-4B5E-9D5F-5E97DD7B8958 Q34283903-619B72DA-767A-4FB0-956F-D14F386B5A66 Q34327594-2639FC29-5ADD-4A3E-8976-DB0F277107F1 Q34400733-792BFE81-BD5E-4097-B021-67C54BB2B07C Q34490600-758F9C7F-2D18-4014-A738-D0292ED5605C Q34538009-6D0B81BE-93D9-4483-AD0E-63D4DB337417 Q34994901-36ABEBBE-C067-40FB-83D6-4D8A063C4536 Q35070434-311B2C3A-E094-4879-AF4D-93499B8248A2 Q35071734-11213E2D-831F-45A7-AB63-42D698C7E904 Q35102211-A0D1B101-7897-4DFD-A7A6-6FD8B8E706E0 Q35153169-22F9027F-005D-4A80-9BF9-3D64F42913B3 Q35164664-41654448-0711-4F9B-98DA-3A40FABC807E Q35591517-5921324E-6FAF-4630-8B59-0486369EE60E Q35826490-6088A60F-74B7-481F-8CD6-21F1F2A989C6 Q35827187-A88CF0B5-8821-4E8B-8A80-FC542B48258C Q35827580-6F187276-A168-464F-AC9B-3C2583F3C9CE Q35844186-EF4752F8-8672-48A4-B169-FE15D1D42660 Q35846680-E1EF9A02-2BF5-4114-BDCB-C41F6B47E003 Q35863379-2ED7E544-3CFE-4D57-9ED0-EC5C6FAA217B Q36120816-A8652DF4-1747-4646-BCDE-E4CF58D4FE48 Q36186945-9C1B627A-BEAE-43D3-92CE-64E430512F33 Q36301589-E89DB615-5674-4AB7-9DBC-94407BF0C769 Q36326210-98A4AB9A-60E0-43BF-B255-4E02678C82B4 Q36349672-C4527B39-8EA7-4604-96C7-4328F47DF14A Q36592129-9DBA5CAF-2EC6-42E0-8ADA-8039D4036184 Q36605135-BD98D524-CB44-43EE-B0FD-0C702C3A3FDC Q36701911-00423DEB-A10B-47E3-AD81-3E61233890A9 Q36895830-1810387E-E6FF-4685-BF7F-3594E409FC72 Q37024001-A435D340-8C7B-4662-9976-8C916DA67DF2 Q37367679-882BE442-DB11-4F4A-8C8B-48C56D10506F Q37550556-883010E1-31E7-4432-A8AB-0EFA351E78BF Q37550561-CB38B47F-3527-4339-A360-9F7B4BE334D3 Q37635181-BDA337D6-777E-4AC4-A1A0-D331B693EE38 Q37857671-ADA388EC-774A-41FB-AD44-962ED95F874E Q37964574-1A639C26-4DFA-45AB-8D14-65476F0666B3

P2860

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

http://www.wikidata.org/entity/Q35803858

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

@ast

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

@en

type

label

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

@ast

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

@en

prefLabel

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

@ast

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

@en

P1433

Q35803858-A03286CA-48BE-47E9-ACDE-B299EECBFAA8

P1476

Q35803858-4B70E329-DF48-4921-A9AD-A3DCB925A987

P2093

Q35803858-33C58687-7EB6-4E29-9B00-C860D966D548

Q35803858-5B646BA6-922F-4186-A898-1F98DB5D0BA1

Q35803858-7469C24F-E5AC-497A-BB7B-01854BF5B1A4

Q35803858-A6476732-7DB8-40A1-A739-3B1DAEFE629D

Q35803858-D39FAA04-0906-45B1-8657-3FD1723E4198

Q35803858-FEB7C87F-5C1E-4A4D-9DFC-7CAE11FE4931

P2860

Q35803858-0462EF2A-B1E4-4DE0-9123-FA1C368DEF67

Q35803858-07DC12E0-3B19-4498-95E4-8929DB407A59

Q35803858-119C3D82-41EC-40E0-99A1-A86994592B24

Q35803858-135DABAD-D08B-42AC-BF75-A054FB679640

Q35803858-1749E09C-662C-415E-891D-E1381BFF56BC

Q35803858-192DECEA-D4CD-41E5-83AB-6825FBCC39DA

Q35803858-1BDADB24-6E11-4990-A78F-9E5CF5994830

Q35803858-2C95CDD1-A7E7-4E86-B3EC-2EF43084FCE0

Q35803858-472210AB-095B-4BFB-89E7-2702DB2C93C6

Q35803858-63347356-A686-4C45-8EB0-084DA402DA98

P304

Q35803858-E3964882-92A2-4A82-8117-25F36961DFD4

P31

Q35803858-F260D6D5-8EC9-42CD-BD31-73C55F5955D0

P356

Q35803858-B7CB14ED-80D0-4808-A2E5-A9372EDED880

P407

Q35803858-D5CCC0EC-B207-444C-A240-92FB3BF21E94

P433

Q35803858-830FCB4C-2BB0-4B05-A5D1-D5835C9187DC

P478

Q35803858-A4A79A33-6559-41F7-8A6C-63153F5C67B7

P50

Q35803858-2E0A7EA5-47A2-45E4-A767-A0CA65DCC879

Q35803858-7CC67D20-CF1E-426A-B4A3-A1F377C31CED

P577

Q35803858-7D85561C-216D-4ADB-8859-321215DD8DE6

P5875

Q35803858-3EC7A43E-A266-4C74-B6FD-193463B64E20

P698

Q35803858-D1821928-2DA5-4210-A108-E4FE06ED230F

P932

Q35803858-6901C7B7-AE4D-47A4-A8F9-5022381F9DC1

P356

J.1365-2125.2002.01591.X

P1433

British Journal of Clinical Pharmacology

P1476

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

@en

P2093

Martin F Fromm

http://www.w3.org/2001/XMLSchema#string

Matthias Schwab

http://www.w3.org/2001/XMLSchema#string

Michel Eichelbaum

http://www.w3.org/2001/XMLSchema#string

Monika Hitzl

http://www.w3.org/2001/XMLSchema#string

Siegfried Drescher

http://www.w3.org/2001/XMLSchema#string

Ulrich Brinkmann

http://www.w3.org/2001/XMLSchema#string

P2860

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine

Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil

Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver

The effect of rifampin administration on the disposition of fexofenadine.

Clinical pharmacology of new histamine H1 receptor antagonists.

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.

P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.

Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria.

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

P304

526-534

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2125.2002.01591.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Elke Schaeffeler

P577

2002-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11376630

http://www.w3.org/2001/XMLSchema#string

P698

11994059

http://www.w3.org/2001/XMLSchema#string

P932

1874364

http://www.w3.org/2001/XMLSchema#string